Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (DE:7V3)
FRANKFURT:7V3
7V3 Stock Chart & Stats
€0.40
>-€0.01(-1.59%)
At close: 4:00 PM EST
€0.40
>-€0.01(-1.59%)
Day’s Range― - ―
52-Week Range€0.06 - €0.37
Previous CloseN/A
Volume0.00
Average Volume (3M)715.00
Market Cap
€94.70M
Enterprise Value€276.13M
Total Cash (Recent Filing)€339.14M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)8.6
Beta0.43
Next Earnings
Feb 20, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding248,611,650
10 Day Avg. Volume0
30 Day Avg. Volume715
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.67
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€1.29Price Target Upside222.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market OpportunityThere are currently no approved bispecifics in the autoimmune space, providing a significant market opportunity for the company.
Pipeline DevelopmentNadunolimab is pivotal study ready, with the development of an IL1RAP-based companion diagnostic assay on track to support a 1L PDAC trial.
Strategic PartnershipsThe CAN10 program acquisition by Otsuka Pharmaceutical provides important external validation and immediate non-dilutive financing to Cantargia.
Bears Say
Clinical Study OutcomesThe final median overall survival (OS) data from the TRIFOUR study confirmed the program's failure in triple-negative breast cancer (TNBC), justifying our prior zero valuation contribution for this indication.
Efficacy ChallengesThe updated survival data from the Phase 1b/2 TRIFOUR study serve as the final confirmation of the program's lack of efficacy in TNBC.
Trial ResultsThe TRIFOUR Phase 2 study in TNBC did not meet its primary ORR endpoint, comparing nadunolimab in combination with chemotherapy vs. chemotherapy alone.
Cantargia AB News
7V3 FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was €0.06 and its highest was €0.37 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is €94.70M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is Feb 20, 2026 which is in 61 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Nov 19, 2025. The company reported €0.099 earnings per share for the quarter, beating the consensus estimate of -€0.016 by €0.114.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Undervalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate is -0.02.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of €0.099 in its last earnings report, beating expectations of -€0.016. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in DE:7V3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cantargia AB
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven by the Interleukin-1 system and is under phase IIa clinical trial; and CAN10, an antibody against IL1RAP for treatment of autoimmune and inflammatory diseases, including systemic sclerosis and myocarditis, and is under preclinical trial. It is also developing CANxx antibodies against IL1RAP. The company has collaboration agreements with Patheon Biologics BV and BioWa Inc. for the manufacture and production of CAN04; and Specialized Medical Services-oncology BV for the clinical study of CAN04. Cantargia AB (publ) was founded in 2010 and is based in Lund, Sweden.
7V3 Stock 12 Month Forecast
Average Price Target
€1.29
▲(222.50% Upside)
Technical Analysis
Oncopeptides AB
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Guard Therapeutics International AB
―
Immunicum AB
―